All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, August 14, 2022
Home » Blogs » BioWorld MedTech Perspectives » When FDA and industry clash: media's prejudices

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / CDRH / FDA

When FDA and industry clash: media's prejudices

July 7, 2011
By Mark McCarty
No Comments

First, just to let you know dear reader, this is a Casey Anthony-free blog posting.

Those who are skeptical of the device industry in this world are legion, but there are a lot of reasons to cast the occasional baleful glance at government as well. What's interesting is how many in the media automatically assume that any clash between FDA and industry is necessarily the fault of industry.

Case in point: I was at the American Diabetes Association annual scientific sessions about two weeks ago and had a conversation with another member of the press. She said more or less that industry is to blame for any problems device makers are having with FDA approval times. I said I had no idea whether the fault lay mostly with one party or the other (or was equally shared by both) because I don't have access to enough information to give me a clear idea of what the aggregate picture looks like.

All the same, this journalist snapped at me, “I've been doing this a long time, and I know.”

My first impulse was to thank her for seeing me as a babe in the woods because while I don't look like Methuselah, I'm not exactly 20-something, either. Another reason for not taking offense was that her retort reminded me of a character in the book “A Confederacy of Dunces,” which was penned by the late John Kennedy Toole. In that book – which is an absolute scream and you should read it if you haven't – the character going by the name Miss Trixie often snarls at the other characters, “Silence!” when they're getting on her readily jangled nerves.

I took the hint from my so-called colleague's rhetorical power play (i.e., I'm older than you and hence you're stupid) and moved along with my workday. I don't pretend to know everything about the world of medical devices and device approvals – not by a long shot – but I know a lot more than most people in my line of work, I promise you that much. Still, there's no point in trying to persuade others of the need to have a little respect for facts or, in this case, an absence of facts. It's almost always a waste of time.

The peculiar thing is that I hear that kind of thing a lot from people in the media, both those in the mainstream media and those in the trade press. Anyone who sticks around in the trades for very long begins to see the number of moving parts and starts to understand that government gets it wrong, too, but I'm not sure such an understanding typically dawns on those working for the major media outlets. Maybe nuance isn't their stock in trade.

My impression is that many in the media think that FDA is the problem child when the agency is pitted against patients or doctors. When FDA and industry butt heads, industry is presumed to be the locus of corruption. The problem is that FDA's medical device center is demonstrably guilty of malfeasance as the dismissals of two former FDAers (Robert Smith, MD, and Julian Nicholas, MD) very strongly suggest, and the agency's sped-up approvals of some cancer drugs have boomeranged, demonstrating that the agency sometimes goes overboard in its efforts to appease patient groups as well. Thus, the hazards of assuming one party or another is automatically at fault are elucidated.

It's a commonplace of modern life that one runs the risk of making a you-know-what out of you-know-who when one assumes anything, but that doesn't slow us down much, does it? Nor should it, not if yours truly wants to avoid joining the ranks of the unemployed.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 12, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 12, 2022.
  • Amvuttra

    Alnylam’s Amvuttra rare disease drug among positive recommendations from Europe’s CHMP

    BioWorld
    Alnylam Pharmaceuticals Inc.’s Amvuttra (vutrisiran), a treatment for the rare disease hereditary transthyretin-mediated amyloidosis, was among medicines...
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing